| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Dan Peer | Q43193344 |
| P2093 | author name string | Assaf Ganoth | |
| Keren Cohen Merimi | |||
| P2860 | cites work | ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal | Q21246014 |
| A multidrug resistance transporter from human MCF-7 breast cancer cells | Q22008574 | ||
| Advances in Homology Protein Structure Modeling | Q22241408 | ||
| Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line | Q24338329 | ||
| Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues | Q24633406 | ||
| Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding | Q24657908 | ||
| VMD: visual molecular dynamics | Q27860554 | ||
| ABC Transporters: From Microorganisms to Man | Q28181688 | ||
| Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target | Q28266775 | ||
| Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma | Q28474030 | ||
| Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity | Q29614981 | ||
| Cancer nanotechnology: opportunities and challenges | Q29615481 | ||
| Nanoparticle therapeutics: an emerging treatment modality for cancer | Q29615628 | ||
| Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles | Q29615957 | ||
| Precision nanomedicine in neurodegenerative diseases | Q47572373 | ||
| Paul Ehrlich's magic bullet concept: 100 years of progress | Q48322740 | ||
| Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. | Q48535535 | ||
| The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. | Q52901931 | ||
| Biochemistry of multidrug resistance mediated by the multidrug transporter | Q29616476 | ||
| Nanocarriers as an emerging platform for cancer therapy | Q29616699 | ||
| Recent advances with liposomes as pharmaceutical carriers | Q29616702 | ||
| Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance | Q29617469 | ||
| Drug delivery systems: entering the mainstream | Q29618136 | ||
| Insights on P-Glycoprotein's Efflux Mechanism Obtained by Molecular Dynamics Simulations. | Q30381678 | ||
| Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. | Q32038879 | ||
| Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model | Q32145219 | ||
| Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump | Q33204719 | ||
| The structure of the multidrug resistance protein 1 (MRP1/ABCC1). crystallization and single-particle analysis | Q33940559 | ||
| Nanoparticles for imaging, sensing, and therapeutic intervention | Q34010233 | ||
| P-glycoprotein: from genomics to mechanism. | Q34272173 | ||
| Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy | Q34326254 | ||
| Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology | Q34328650 | ||
| A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants | Q34488592 | ||
| Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. | Q34559072 | ||
| Mammalian ABC transporters in health and disease | Q34667449 | ||
| Homology modeling of breast cancer resistance protein (ABCG2). | Q34745874 | ||
| Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models | Q34770116 | ||
| Role of transmembrane segment 5 and extracellular loop 3 in the homodimerization of human ABCC1 | Q34984493 | ||
| Ovarian cancer: strategies for overcoming resistance to chemotherapy | Q35166813 | ||
| Cell biological mechanisms of multidrug resistance in tumors | Q35179585 | ||
| Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance | Q35642041 | ||
| Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. | Q35676793 | ||
| Tumour vascular targeting | Q36146905 | ||
| Fluoxetine and reversal of multidrug resistance | Q36192969 | ||
| Long-circulating polymeric nanovectors for tumor-selective gene delivery | Q36314788 | ||
| Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). | Q36357541 | ||
| An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy | Q36384930 | ||
| New light on multidrug binding by an ATP-binding-cassette transporter | Q36424404 | ||
| Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. | Q36536479 | ||
| Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine | Q36629939 | ||
| Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? | Q36662084 | ||
| Thermo- and pH-responsive polymers in drug delivery | Q36663097 | ||
| Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). | Q36691571 | ||
| Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo | Q36749553 | ||
| Role of the MRP1/ABCC1 multidrug transporter protein in cancer | Q37034313 | ||
| Protein nanoparticles as drug carriers in clinical medicine | Q37142688 | ||
| Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line | Q37507270 | ||
| Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. | Q37844303 | ||
| Special delivery: targeted therapy with small RNAs. | Q37864924 | ||
| Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. | Q37938291 | ||
| Mammalian multidrug-resistance proteins (MRPs). | Q37941757 | ||
| Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends | Q37946340 | ||
| Polysaccharides as building blocks for nanotherapeutics | Q37956480 | ||
| Doxil®--the first FDA-approved nano-drug: lessons learned | Q38000876 | ||
| RNAi-based nanomedicines for targeted personalized therapy | Q38043189 | ||
| The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo | Q38054216 | ||
| A daunting task: manipulating leukocyte function with RNAi | Q38095502 | ||
| Omics-based nanomedicine: the future of personalized oncology | Q38128637 | ||
| Rationally designed nanovehicles to overcome cancer chemoresistance | Q38129698 | ||
| Molecular pharmacology of ABCG2 and its role in chemoresistance | Q38135946 | ||
| Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future | Q38139596 | ||
| Precision medicine--delivering the goods? | Q38207405 | ||
| Quaternized starch-based carrier for siRNA delivery: from cellular uptake to gene silencing. | Q38998692 | ||
| Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles. | Q39020856 | ||
| Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters | Q39027419 | ||
| Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. | Q39682110 | ||
| In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy | Q39776451 | ||
| A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo | Q40013790 | ||
| The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone | Q40147815 | ||
| Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). | Q40426499 | ||
| Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models | Q40502587 | ||
| Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding | Q42691597 | ||
| ABC transporters in cancer: more than just drug efflux pumps. | Q43193922 | ||
| Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study | Q43806484 | ||
| Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models | Q44706686 | ||
| Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport | Q44854938 | ||
| Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen | Q46319065 | ||
| Nucleotide-induced structural changes in P-glycoprotein observed by electron microscopy. | Q46416788 | ||
| Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Gr | Q46898523 | ||
| Molecular modeling of the human multidrug resistance protein 1 (MRP1/ABCC1). | Q46916652 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanomedicine | Q261659 |
| multiple drug resistance | Q643839 | ||
| P304 | page(s) | 223-238 | |
| P577 | publication date | 2014-09-16 | |
| P1433 | published in | Expert Opinion on Drug Delivery | Q5421203 |
| P1476 | title | Overcoming multidrug resistance with nanomedicines | |
| P478 | volume | 12 |
| Q30362001 | Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment. |
| Q58765211 | Downregulation of hypermethylated in cancer-1 by - promotes adriamycin resistance in breast cancer cells |
| Q48358592 | In Vivo Targeting and Positron Emission Tomography Imaging of Tumor with Intrinsically Radioactive Metal-Organic Frameworks Nanomaterials. |
| Q39323096 | Nanomaterial-Enabled Cancer Therapy |
| Q38463092 | Nanomedicine as an emerging platform for metastatic lung cancer therapy. |
| Q37407242 | Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9. |
| Q39177662 | Spotlight on the delivery of photosensitizers: different approaches for photodynamic-based therapies. |
| Q55022875 | Therapeutic polymeric nanoparticles and the methods of making and using thereof: a patent evaluation of WO2015036792. |
| Q26777880 | Therapies targeting cancer stem cells: Current trends and future challenges |
Search more.